
    
      The primary endpoints is to compare the progression-free survival (PFS) of pemetrexed plus
      carboplatin combined with gefitinib to gefitinib alone as first-line therapy for lung
      adenocarcinoma.

      In addition, the overall survival and safety index will be collected for analyses.
    
  